Close Menu

NEW YORK (GenomeWeb) – A newly published  multi-institutional cohort study has validated Epic Sciences' circulating tumor cell-based AR-V7 test, now marketed by Genomic Health as Oncotype DX AR-V7 Nucleus Detect.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.